[1] 谢幸,苟文丽. 妇产科学[M]. 8版. 北京:人民卫生出版社, 2013:313-317.[2] Ito K,Sasano H,Yabuki N,et al.Immunohis to chemical study of Ki-67 and DNA topoisomerase Ⅱ in human endometrium[J].Mod Pathol,1997, 10(4):289-294.[3] 马大烈,白辰光.免疫组织化学阳性标记结果的观察和判定[J].临床与实验病理学杂志,2003,19(5): 557-559.[4] 张惠娇,戴慧晶,沈洪武.雌孕激素受体、p53、C-erbB-2在子宫内膜癌的表达及临床意义[J].肿瘤学杂志,2004,10(2):72-74.[5] Prenzel N, Fischer OM, Streit S,et al. The epidermal growth factorreceptor family as a central element for cellular signal transduction and diversification[J]. Endocr Relat Cancer,2001,8(1) : 11-31.[6] Gerdes J, Lemke H, Baisch H,et al. Cell cycle analysis of a cell proliferation associated human unclear antigen defined by the monoclonal antibody Ki-67[J].J Immunol,1984,133(13):1710-1715.[7] Pilka R,Mickova I.Expression of p53, Ki-67,Bcl-2,C-erbB-2, estrogen, and progesterone receptors in endometrial cancer[J].Ceska Gynekol,2008,73(4):222-227. [8] 黄世勇,吴翠云.子宫内膜癌组织中C-erbB-2及Ki-67表达的临床意义[J]. 中国医药指南,2011,18(1):40-41.[9] 刘颖,刘慧.C-erbB-2与Ki-67在子宫内膜癌组织中的表达及相关性研究[J].实用癌症杂志, 2010,25(4):366-368.(2014-01-16收稿 2014-04-20修回) |